Symbols / INDV Stock $34.43 +0.35% Indivior Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
INDV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Joseph J. Ciaffoni
Exch · Country NMS · United States
Market Cap 4.20B
Enterprise Value 4.45B
Income 210.00M
Sales 1.24B
FCF (ttm) 221.75M
Book/sh -0.78
Cash/sh 1.56
Employees 827
Insider 10d —
IPO Dec 29, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 20.99
Forward P/E 10.11
PEG —
P/S 3.39
P/B -43.92
P/C —
EV/EBITDA 11.20
EV/Sales 3.59
Quick Ratio 0.49
Current Ratio 0.71
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 1.64
EPS next Y 3.40
EPS Growth 3.76%
Revenue Growth 19.70%
EPS Gr Q/Q 3.86%
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-02-26
ROA 19.22%
ROE —
ROIC —
Gross Margin 84.02%
Oper. Margin 37.15%
Profit Margin 16.95%
Shs Outstand 121.92M
Shs Float 106.45M
Insider Own 1.39%
Instit Own 87.24%
Short Float 13.50%
Short Ratio 5.45
Short Interest 13.93M
52W High 38.00
vs 52W High -9.39%
52W Low 10.63
vs 52W Low 223.89%
Beta 1.21
Impl. Vol. 83.84%
Rel Volume 0.60
Avg Volume 2.39M
Volume 1.43M
Target (mean) $48.17
Tgt Median $49.00
Tgt Low $42.00
Tgt High $54.00
# Analysts 6
Recom Strong_buy
Prev Close $34.31
Price $34.43
Change 0.35%
About

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$48.17
Mean price target
2. Current target
$34.43
Latest analyst target
3. DCF / Fair value
$32.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$34.43
Low
$42.00
High
$54.00
Mean
$48.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-12 main HC Wainwright & Co. Buy → Buy $48
2025-10-31 reit Piper Sandler Overweight → Overweight $41
2025-10-30 main HC Wainwright & Co. Buy → Buy $35
2025-08-27 main Craig-Hallum Buy → Buy $34
2025-08-06 init HC Wainwright & Co. — → Buy $28
2025-06-30 main Craig-Hallum Buy → Buy $22
2025-03-06 main Piper Sandler Overweight → Overweight $13
2024-10-25 reit Piper Sandler Overweight → Overweight $16
2024-10-11 main Craig-Hallum Buy → Buy $16
2024-10-11 reit Piper Sandler Overweight → Overweight $15
2024-09-13 reit Piper Sandler Overweight → Overweight $22
2024-07-23 init Piper Sandler — → Overweight $22
2024-07-10 main Craig-Hallum Buy → Buy $24
2024-04-03 init Craig-Hallum — → Buy $37
News
RSS: Latest INDV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 RYAN BARBARA A. Director — 8 $31.08 $249
2026-03-13 PREBLICK RYAN Chief Financial Officer — 6,302 — —
2026-03-09 RYAN BARBARA A. Director — 31 $32.56 $1,009
2026-03-06 KINGSLEY STUART A Director — 940 $31.86 $29,953
2026-03-03 BURRIS JEFFREY W Officer — 79,893 — —
2026-03-03 HEIDBREDER CHRISTIAN Officer — 101,544 — —
2026-03-03 ANDERSON WOODROW D Officer — 24,310 — —
2026-03-03 PREBLICK RYAN Chief Financial Officer — 86,949 — —
2026-02-10 CIAFFONI JOSEPH J Chief Executive Officer — 79,976 $0.00 $0
2026-02-10 BURRIS JEFFREY W Officer — 26,897 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,239.00
+4.29%
1,188.00
+8.69%
1,093.00
+21.31%
901.00
Operating Revenue
1,239.00
+4.29%
1,188.00
+8.69%
1,093.00
+21.31%
901.00
Cost Of Revenue
246.00
+6.49%
231.00
+32.76%
174.00
+15.23%
151.00
Reconciled Cost Of Revenue
246.00
+6.49%
231.00
+32.76%
174.00
+15.23%
151.00
Gross Profit
993.00
+3.76%
957.00
+4.13%
919.00
+22.53%
750.00
Operating Expense
728.00
+0.69%
723.00
+7.59%
672.00
+25.61%
535.00
Research And Development
97.00
-9.35%
107.00
-7.76%
116.00
+56.76%
74.00
Selling General And Administration
634.00
+3.59%
612.00
+8.32%
565.00
+20.47%
469.00
Selling And Marketing Expense
315.00
+23.53%
255.00
+8.05%
236.00
+8.26%
218.00
General And Administrative Expense
319.00
-10.64%
357.00
+8.51%
329.00
+31.08%
251.00
Other Gand A
319.00
-10.64%
357.00
+8.51%
329.00
+31.08%
251.00
Other Operating Expenses
-3.00
-175.00%
4.00
+144.44%
-9.00
-12.50%
-8.00
Total Expenses
974.00
+2.10%
954.00
+12.77%
846.00
+23.32%
686.00
Operating Income
265.00
+13.25%
234.00
-5.26%
247.00
+14.88%
215.00
Total Operating Income As Reported
262.00
+589.47%
38.00
+125.00%
-152.00
-87.65%
-81.00
EBITDA
304.00
+241.57%
89.00
+193.68%
-95.00
-106.52%
-46.00
Normalized EBITDA
307.00
+7.72%
285.00
-6.86%
306.00
+22.40%
250.00
Reconciled Depreciation
20.00
-28.57%
28.00
+86.67%
15.00
-6.25%
16.00
EBIT
284.00
+365.57%
61.00
+155.45%
-110.00
-77.42%
-62.00
Total Unusual Items
-3.00
+98.47%
-196.00
+51.12%
-401.00
-35.47%
-296.00
Total Unusual Items Excluding Goodwill
-3.00
+98.47%
-196.00
+51.12%
-401.00
-35.47%
-296.00
Special Income Charges
-3.00
+98.47%
-196.00
+51.12%
-401.00
-35.47%
-296.00
Other Special Charges
3.00
-98.47%
196.00
-51.12%
401.00
+35.47%
296.00
Restructuring And Mergern Acquisition
—
1.00
-99.38%
162.00
0.00
Net Income
210.00
+2900.00%
7.00
+105.56%
-126.00
-186.36%
-44.00
Pretax Income
239.00
+1095.00%
20.00
+113.79%
-145.00
-62.92%
-89.00
Net Non Operating Interest Income Expense
-23.00
-27.78%
-18.00
-325.00%
8.00
+200.00%
-8.00
Interest Expense Non Operating
45.00
+9.76%
41.00
+17.14%
35.00
+29.63%
27.00
Net Interest Income
-23.00
-27.78%
-18.00
-325.00%
8.00
+200.00%
-8.00
Interest Expense
45.00
+9.76%
41.00
+17.14%
35.00
+29.63%
27.00
Interest Income Non Operating
22.00
-4.35%
23.00
-46.51%
43.00
+126.32%
19.00
Interest Income
22.00
-4.35%
23.00
-46.51%
43.00
+126.32%
19.00
Other Income Expense
-3.00
—
-401.00
-35.47%
-296.00
Tax Provision
29.00
+123.08%
13.00
+168.42%
-19.00
+56.82%
-44.00
Tax Rate For Calcs
0.00
-41.90%
0.00
+60.26%
0.00
-37.60%
0.00
Tax Effect Of Unusual Items
-0.37
+99.11%
-41.16
+21.67%
-52.54
+15.47%
-62.16
Net Income Including Noncontrolling Interests
210.00
+2900.00%
7.00
+105.56%
-126.00
-180.00%
-45.00
Net Income From Continuing Operation Net Minority Interest
210.00
+2900.00%
7.00
+105.56%
-126.00
-186.36%
-44.00
Net Income From Continuing And Discontinued Operation
210.00
+2900.00%
7.00
+105.56%
-126.00
-186.36%
-44.00
Net Income Continuous Operations
210.00
+2900.00%
7.00
+105.56%
-126.00
-180.00%
-45.00
Normalized Income
212.63
+31.39%
161.84
-27.25%
222.46
+17.18%
189.84
Net Income Common Stockholders
210.00
+2900.00%
7.00
+105.56%
-126.00
-186.36%
-44.00
Otherunder Preferred Stock Dividend
—
0.00
0.00
0.00
Diluted EPS
1.64
+555.56%
-0.36
-3700.00%
0.01
+102.63%
-0.38
Basic EPS
1.68
+566.67%
-0.36
-3700.00%
0.01
+102.63%
-0.38
Basic Average Shares
125.00
-5.52%
132.31
-3.64%
137.31
-1.23%
139.01
Diluted Average Shares
128.00
-3.26%
132.31
-6.69%
141.80
-2.62%
145.62
Diluted NI Availto Com Stockholders
210.00
+2900.00%
7.00
+105.56%
-126.00
-186.36%
-44.00
Depreciation And Amortization In Income Statement
—
—
—
—
Depreciation Income Statement
—
—
—
—
Total Other Finance Cost
—
—
1.00
+200.00%
-1.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
1,316.00
-25.23%
1,760.00
-0.51%
1,769.00
—
Current Assets
827.00
-34.68%
1,266.00
+0.56%
1,259.00
—
Cash Cash Equivalents And Short Term Investments
320.00
-21.95%
410.00
-54.09%
893.00
—
Cash And Cash Equivalents
319.00
+0.95%
316.00
-59.17%
774.00
—
Other Short Term Investments
1.00
-98.94%
94.00
-21.01%
119.00
—
Receivables
287.00
—
—
—
Accounts Receivable
254.00
+0.00%
254.00
+15.45%
220.00
—
Gross Accounts Receivable
257.00
+0.39%
256.00
+15.32%
222.00
—
Allowance For Doubtful Accounts Receivable
-3.00
-50.00%
-2.00
+0.00%
-2.00
—
Taxes Receivable
33.00
0.00
-100.00%
5.00
—
Inventory
178.00
+31.85%
135.00
+18.42%
114.00
—
Raw Materials
33.00
-13.16%
38.00
+40.74%
27.00
—
Work In Process
51.00
+50.00%
34.00
-19.05%
42.00
—
Finished Goods
94.00
+49.21%
63.00
+40.00%
45.00
—
Prepaid Assets
31.00
+34.78%
23.00
+64.29%
14.00
—
Restricted Cash
0.00
-100.00%
415.00
—
—
Other Current Assets
11.00
-78.85%
52.00
+300.00%
13.00
—
Total Non Current Assets
489.00
-1.01%
494.00
-3.14%
510.00
—
Net PPE
139.00
+12.10%
124.00
+45.88%
85.00
—
Gross PPE
229.00
+11.71%
205.00
+26.54%
162.00
—
Accumulated Depreciation
-90.00
-11.11%
-81.00
-5.19%
-77.00
—
Properties
0.00
0.00
0.00
—
Land And Improvements
76.00
+16.92%
65.00
+27.45%
51.00
—
Buildings And Improvements
—
11.00
+22.22%
9.00
-25.00%
12.00
Machinery Furniture Equipment
76.00
-1.30%
77.00
-24.51%
102.00
—
Construction In Progress
38.00
+65.22%
23.00
—
—
Other Properties
39.00
-2.50%
40.00
—
—
Goodwill And Other Intangible Assets
7.00
-46.15%
13.00
-81.43%
70.00
—
Goodwill
2.00
-60.00%
5.00
0.00
—
Other Intangible Assets
5.00
-37.50%
8.00
-88.57%
70.00
-14.63%
82.00
Investments And Advances
—
—
—
—
Non Current Deferred Assets
277.00
-3.82%
288.00
—
—
Non Current Deferred Taxes Assets
277.00
-3.82%
288.00
+31.51%
219.00
—
Non Current Prepaid Assets
—
19.00
-5.00%
20.00
-9.09%
22.00
Other Non Current Assets
39.00
+39.29%
28.00
+55.56%
18.00
—
Total Liabilities Net Minority Interest
1,653.00
-15.32%
1,952.00
+13.62%
1,718.00
—
Current Liabilities
924.00
-28.37%
1,290.00
+26.59%
1,019.00
—
Payables And Accrued Expenses
824.00
-29.39%
1,167.00
—
—
Payables
93.00
+25.68%
74.00
+21.31%
61.00
—
Accounts Payable
63.00
+61.54%
39.00
+18.18%
33.00
—
Other Payable
—
28.00
+600.00%
4.00
-96.49%
114.00
Current Accrued Expenses
731.00
-33.12%
1,093.00
+93.45%
565.00
—
Pensionand Other Post Retirement Benefit Plans Current
60.00
-16.67%
72.00
—
—
Total Tax Payable
30.00
-14.29%
35.00
+45.83%
24.00
—
Income Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
28.00
+133.33%
12.00
+9.09%
11.00
—
Current Debt
18.00
+500.00%
3.00
+0.00%
3.00
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
10.00
+11.11%
9.00
+12.50%
8.00
—
Other Current Liabilities
12.00
-69.23%
39.00
-50.63%
79.00
—
Total Non Current Liabilities Net Minority Interest
729.00
+10.12%
662.00
-5.29%
699.00
—
Long Term Debt And Capital Lease Obligation
347.00
+28.04%
271.00
+1.88%
266.00
—
Long Term Debt
315.00
+32.91%
237.00
+0.00%
237.00
—
Long Term Capital Lease Obligation
32.00
-5.88%
34.00
+17.24%
29.00
—
Long Term Provisions
—
12.00
+140.00%
5.00
-93.42%
76.00
Other Non Current Liabilities
17.00
-46.88%
32.00
-92.52%
428.00
—
Stockholders Equity
-337.00
-75.52%
-192.00
-476.47%
51.00
—
Common Stock Equity
-337.00
-75.52%
-192.00
-476.47%
51.00
—
Capital Stock
62.00
-8.82%
68.00
+0.00%
68.00
—
Common Stock
62.00
-8.82%
68.00
+0.00%
68.00
—
Share Issued
124.90
-8.51%
136.53
+0.03%
136.48
—
Ordinary Shares Number
124.90
-8.51%
136.53
+0.03%
136.48
—
Treasury Shares Number
0.00
0.00
0.00
0.00
Additional Paid In Capital
90.00
+2.27%
88.00
+528.57%
14.00
—
Retained Earnings
-443.00
-50.17%
-295.00
-122.64%
1,303.00
—
Gains Losses Not Affecting Retained Earnings
—
-53.00
—
—
Other Equity Adjustments
—
-53.00
—
—
Total Equity Gross Minority Interest
-337.00
-75.52%
-192.00
-476.47%
51.00
—
Total Capitalization
-22.00
-148.89%
45.00
-84.38%
288.00
—
Working Capital
-97.00
-304.17%
-24.00
-110.00%
240.00
—
Invested Capital
-4.00
-108.33%
48.00
-83.51%
291.00
—
Total Debt
375.00
+32.51%
283.00
+2.17%
277.00
—
Net Debt
14.00
—
—
—
Capital Lease Obligations
42.00
-2.33%
43.00
+16.22%
37.00
—
Net Tangible Assets
-344.00
-67.80%
-205.00
-978.95%
-19.00
—
Tangible Book Value
-344.00
-67.80%
-205.00
-978.95%
-19.00
—
Available For Sale Securities
—
—
98.00
—
Current Provisions
—
407.00
+34.32%
303.00
+5960.00%
5.00
Held To Maturity Securities
27.00
-34.15%
41.00
-58.16%
98.00
0.00
Investmentin Financial Assets
27.00
-34.15%
41.00
-58.16%
98.00
0.00
Non Current Accrued Expenses
365.00
+1.67%
359.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-27.00
-175.00%
36.00
+112.00%
-300.00
-7400.00%
-4.00
Cash Flow From Continuing Operating Activities
-27.00
—
-299.00
-9866.67%
-3.00
Net Income From Continuing Operations
210.00
+2900.00%
7.00
+105.56%
-126.00
-186.36%
-44.00
Depreciation Amortization Depletion
20.00
-28.57%
28.00
+86.67%
15.00
-6.25%
16.00
Depreciation
20.00
-28.57%
28.00
+86.67%
15.00
+7.14%
14.00
Amortization Cash Flow
—
—
12.00
+71.43%
7.00
Depreciation And Amortization
20.00
-28.57%
28.00
+86.67%
15.00
-6.25%
16.00
Amortization Of Intangibles
—
—
12.00
—
Other Non Cash Items
—
1.00
-99.38%
161.00
—
Stock Based Compensation
26.00
+8.33%
24.00
+14.29%
21.00
+31.25%
16.00
Asset Impairment Charge
19.00
—
—
—
Deferred Tax
-46.00
-757.14%
7.00
+110.94%
-64.00
+39.05%
-105.00
Deferred Income Tax
-46.00
-757.14%
7.00
+110.94%
-64.00
—
Operating Gains Losses
1.00
—
-10.00
—
Gain Loss On Investment Securities
—
9.00
—
—
Unrealized Gain Loss On Investment Securities
0.00
—
—
—
Net Foreign Currency Exchange Gain Loss
1.00
+150.00%
-2.00
+80.00%
-10.00
-150.00%
-4.00
Gain Loss On Sale Of PPE
—
—
0.00
+100.00%
-1.00
Change In Working Capital
-257.00
-458.70%
-46.00
+84.51%
-297.00
-351.69%
118.00
Change In Receivables
3.00
+400.00%
-1.00
+96.97%
-33.00
-57.14%
-21.00
Changes In Account Receivables
3.00
—
—
—
Change In Inventory
18.00
+141.86%
-43.00
-616.67%
-6.00
+80.00%
-30.00
Change In Payables And Accrued Expense
-368.00
—
50.00
-74.62%
197.00
Change In Accrued Expense
-368.00
+4.91%
-387.00
-874.00%
50.00
-74.62%
197.00
Change In Payable
—
—
115.00
+217.35%
-98.00
Change In Other Working Capital
—
—
49.00
—
Change In Other Current Assets
49.00
-87.00%
377.00
+190.19%
-418.00
-705.80%
69.00
Change In Other Current Liabilities
41.00
+412.50%
8.00
-92.73%
110.00
+213.40%
-97.00
Investing Cash Flow
-66.00
-195.65%
69.00
+172.63%
-95.00
+57.21%
-222.00
Cash Flow From Continuing Investing Activities
-67.00
—
-95.00
+57.21%
-222.00
Net PPE Purchase And Sale
-66.00
-127.59%
-29.00
-262.50%
-8.00
-60.00%
-5.00
Purchase Of PPE
-66.00
-127.59%
-29.00
-262.50%
-8.00
-60.00%
-5.00
Sale Of PPE
—
1.00
-99.38%
162.00
0.00
Capital Expenditure
-67.00
-116.13%
-31.00
+41.51%
-53.00
-960.00%
-5.00
Net Investment Purchase And Sale
0.00
-100.00%
100.00
+19.05%
84.00
+138.53%
-218.00
Purchase Of Investment
-20.00
-17.65%
-17.00
+62.22%
-45.00
+81.63%
-245.00
Sale Of Investment
20.00
-82.91%
117.00
-9.30%
129.00
+377.78%
27.00
Net Business Purchase And Sale
0.00
0.00
+100.00%
-129.00
0.00
Purchase Of Business
0.00
0.00
+100.00%
-129.00
0.00
Net Intangibles Purchase And Sale
-1.00
+50.00%
-2.00
+95.56%
-45.00
0.00
Purchase Of Intangibles
-1.00
+50.00%
-2.00
+95.56%
-45.00
0.00
Net Other Investing Changes
1.00
+200.00%
-1.00
-133.33%
3.00
+200.00%
1.00
Financing Cash Flow
-30.00
+70.59%
-102.00
-59.38%
-64.00
+36.63%
-101.00
Cash Flow From Continuing Financing Activities
-31.00
—
-64.00
+36.63%
-101.00
Net Issuance Payments Of Debt
-17.00
-118.48%
92.00
+866.67%
-12.00
-300.00%
-3.00
Issuance Of Debt
0.00
-100.00%
332.00
0.00
0.00
Repayment Of Debt
-17.00
+92.92%
-240.00
-1900.00%
-12.00
-300.00%
-3.00
Long Term Debt Issuance
0.00
-100.00%
332.00
0.00
0.00
Long Term Debt Payments
-17.00
+92.92%
-240.00
-1900.00%
-12.00
-300.00%
-3.00
Net Long Term Debt Issuance
-17.00
-118.48%
92.00
+866.67%
-12.00
-300.00%
-3.00
Net Common Stock Issuance
-9.00
+94.71%
-170.00
-466.67%
-30.00
+65.91%
-88.00
Common Stock Payments
-11.00
+93.64%
-173.00
-424.24%
-33.00
+63.33%
-90.00
Repurchase Of Capital Stock
-11.00
+93.64%
-173.00
-424.24%
-33.00
+63.33%
-90.00
Net Other Financing Charges
-4.00
+83.33%
-24.00
-9.09%
-22.00
-120.00%
-10.00
Changes In Cash
-123.00
-4200.00%
3.00
+100.65%
-459.00
-40.37%
-327.00
Effect Of Exchange Rate Changes
-1.00
0.00
-100.00%
1.00
+200.00%
-1.00
Beginning Cash Position
319.00
+0.95%
316.00
-59.17%
774.00
-29.76%
1,102.00
End Cash Position
195.00
-38.87%
319.00
+0.95%
316.00
-59.17%
774.00
Free Cash Flow
-94.00
-1980.00%
5.00
+101.42%
-353.00
-3822.22%
-9.00
Common Stock Issuance
2.00
-33.33%
3.00
+0.00%
3.00
+50.00%
2.00
Interest Paid CFO
—
—
-32.00
-33.33%
-24.00
Interest Received CFO
—
—
42.00
+180.00%
15.00
Issuance Of Capital Stock
2.00
-33.33%
3.00
+0.00%
3.00
+50.00%
2.00
Sale Of Intangibles
—
—
0.00
-100.00%
1.00
Taxes Refund Paid
—
—
-55.00
+17.91%
-67.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category